Healthcare firm Fresenius Q3 revenue rises on Kabi growth; lifts outlook

Fresenius SE & Co. KGaA

Yesterday 05:55

Overview
Germany healthcare firm's Q3 organic revenue grew 5%, driven by Kabi and Helios units
Core EPS rose 14% in constant currency, supported by operating gains and lower interest expense
Company improved FY 2026 core EPS and EBIT margin guidance; signed major biosimilars deal with WuXi

Outlook
Fresenius raises FY/26 Core EPS growth outlook to upper half of 10%-15% range
Company now expects FY/26 Group EBIT margin above 11.5%
Fresenius expects FY/26 organic revenue growth of 4%-7%

Result Drivers
KABI GROWTH VECTORS - Fresenius said Kabi's Biopharma, MedTech and Nutrition segments drove strong organic growth, with Biopharma up 29% and Growth Vectors contributing more than half of Kabi EBIT
HELIOS EBIT GAINS - Helios EBIT grew 19% in constant currency, supported by solid revenue growth, cost management, and temporary surcharge benefit in Germany
INTEREST EXPENSE REDUCTION - Company said further debt reduction lowered interest expense, supporting Core EPS growth

Company press release: ID:nEQbfY4wDa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
 
EUR 5.80 bln
 
Q3 Adjusted EBIT
 
EUR 638 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Fresenius SE & Co. KGaA is €57.00, about 16.8% above its November 3 closing price of €48.81
The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 12 three months ago

Reuters Recommended Reads
Nov 2 - Fresenius signs biosimilars pipeline agreement with WuXi Biologics
Nov 3 - Bayer raises 2026 profit outlook as pharma business beats expectations

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)